300 related articles for article (PubMed ID: 30096458)
1. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
2. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
3. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
[TBL] [Abstract][Full Text] [Related]
4. Participation of BMI-1 protein in cancer.
Zaczek A; Jóźwiak P; Krześlak A
Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):811-824. PubMed ID: 28931748
[TBL] [Abstract][Full Text] [Related]
5. ERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer.
Wei XL; Dou XW; Bai JW; Luo XR; Qiu SQ; Xi DD; Huang WH; Du CW; Man K; Zhang GJ
Oncotarget; 2015 Aug; 6(25):21704-17. PubMed ID: 26023734
[TBL] [Abstract][Full Text] [Related]
6. Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
Patel N; Garikapati KR; Makani VKK; Nair AD; Vangara N; Bhadra U; Pal Bhadra M
PLoS One; 2018; 13(2):e0190245. PubMed ID: 29394261
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Li Z; Wang Y; Yuan C; Zhu Y; Qiu J; Zhang W; Qi B; Wu H; Ye J; Jiang H; Yang J; Cheng J
Lab Invest; 2014 Dec; 94(12):1431-45. PubMed ID: 25286028
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
9. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
Cho JH; Dimri M; Dimri GP
J Biol Chem; 2015 Apr; 290(16):10555-67. PubMed ID: 25737447
[TBL] [Abstract][Full Text] [Related]
11. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
13. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.
Gergely JE; Dorsey AE; Dimri GP; Dimri M
Mol Carcinog; 2018 Jul; 57(7):831-841. PubMed ID: 29528145
[TBL] [Abstract][Full Text] [Related]
14. Effects and mechanism of microRNA‑218 against lung cancer.
Chen Y; Yang JL; Xue ZZ; Cai QC; Hou C; Li HJ; Zhao LX; Zhang Y; Gao CW; Cong L; Wang TZ; Chen DM; Li GS; Luo SQ; Yao Q; Yang CJ; Zhu QS; Cao CH
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179084
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection.
Wu KJ; Yang MH
Biosci Rep; 2011 Dec; 31(6):449-55. PubMed ID: 21919891
[TBL] [Abstract][Full Text] [Related]
16. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.
Wang R; Fan H; Sun M; Lv Z; Yi W
Technol Cancer Res Treat; 2022; 21():15330338211070689. PubMed ID: 35072573
[TBL] [Abstract][Full Text] [Related]
17. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
18. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
19. MUC1-C activates BMI1 in human cancer cells.
Hiraki M; Maeda T; Bouillez A; Alam M; Tagde A; Hinohara K; Suzuki Y; Markert T; Miyo M; Komura K; Ahmad R; Rajabi H; Kufe D
Oncogene; 2017 May; 36(20):2791-2801. PubMed ID: 27893710
[TBL] [Abstract][Full Text] [Related]
20. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
Davies AH; Reipas KM; Pambid MR; Berns R; Stratford AL; Fotovati A; Firmino N; Astanehe A; Hu K; Maxwell C; Mills GB; Dunn SE
Stem Cells; 2014 Jun; 32(6):1437-50. PubMed ID: 24648416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
